Alumis Inc. (NASDAQ:ALMS - Free Report) - Analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for Alumis in a research report issued on Thursday, March 20th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($1.29) per share for the quarter, down from their prior forecast of ($0.99). HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Alumis' current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis' Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.01) EPS, Q4 2025 earnings at ($1.01) EPS and FY2025 earnings at ($4.26) EPS.
A number of other analysts have also issued reports on ALMS. Cantor Fitzgerald reiterated an "overweight" rating on shares of Alumis in a research note on Thursday, March 20th. Oppenheimer began coverage on Alumis in a research report on Thursday, January 30th. They set an "outperform" rating and a $32.00 price objective for the company. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Alumis presently has an average rating of "Buy" and a consensus price target of $26.00.
Check Out Our Latest Analysis on ALMS
Alumis Price Performance
ALMS traded down $0.22 during mid-day trading on Monday, hitting $4.70. 755,477 shares of the stock were exchanged, compared to its average volume of 276,772. The firm's fifty day moving average is $5.49 and its two-hundred day moving average is $8.40. Alumis has a 1-year low of $3.18 and a 1-year high of $13.53.
Institutional Trading of Alumis
Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets purchased a new position in Alumis in the third quarter worth $27,000. MetLife Investment Management LLC acquired a new position in shares of Alumis during the 3rd quarter worth $89,000. Wells Fargo & Company MN increased its holdings in shares of Alumis by 77.1% in the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company's stock valued at $69,000 after purchasing an additional 3,823 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Alumis during the fourth quarter worth about $79,000. Finally, Marshall Wace LLP acquired a new position in Alumis during the fourth quarter worth about $108,000.
Alumis Company Profile
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Articles
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
